Prett

What Prett does

PreTT ApS is a Danish preclinical biotechnology company founded in 2022 and headquartered at the BioInnovation Institute in Copenhagen. The company is developing a proprietary pretargeted radioligand therapy (RLT) platform designed to treat solid tumors by separating tumor-targeting from cytotoxic payload delivery. The approach relies on a two-step administration sequence: a tumor-targeting ligand pretargets the cancer, followed by a rapidly localizing radioactive payload that binds the pretargeted site. This decoupling is intended to reduce off-target radiation exposure relative to conventional directly-labeled RLTs and to enable the use of short-lived alpha-emitting radionuclides that would otherwise be incompatible with conventional targeting kinetics.

PreTT's lead program, PRE-BREACH, applies this platform to glioblastoma, an aggressive brain cancer with limited treatment options. The program is built around a blood-brain barrier (BBB) shuttle mechanism that enables the pretargeted ligand and the subsequent alpha-emitting payload to reach intracranial tumors. The program is being advanced through a named consortium with the University of Copenhagen, Rigshospitalet, Curasight, and PanTarg, and has received a DKK 31.2 million grant from Innovation Fund Denmark to support preclinical development toward first-in-human trials, which the company targets by 2030. The scientific leadership is provided by co-founders Andreas Kjær (CMO), a professor of clinical physiology and nuclear medicine at the University of Copenhagen and Rigshospitalet, and Matthias Herth (CSO), a professor of radiopharmaceutical chemistry at the University of Copenhagen.

PreTT is pre-revenue and operates a typical preclinical biotech business model in which value is created through grant and equity financing used to advance pipeline assets, with future revenue expected to come from out-licensing, pharma partnerships, or co-development deals rather than direct product sales. The company has 1–10 employees, is supported by BioInnovation Institute incubation, and as of February 2026 is led by CEO Dr. Natalia Herrero Alvarez, who succeeded co-founder Francesco Sergi-Lindell.

Name

Prett

Legal name

PreTT ApS

Website

https://pre-tt.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

PreTT ApS is a Copenhagen-based preclinical biotech developing a proprietary pretargeted radioligand therapy platform for cancer, with lead program PRE-BREACH targeting glioblastoma via a blood-brain barrier shuttle and alpha-emitting radionuclides.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals / Cancer Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industry

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)

Keywords

• Radioligand therapy
• Pretargeted radioimmunotherapy
• Cancer therapeutics development
• Glioblastoma treatment platform
• Pharmaceutical research

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Therapeutic Development & Licensing: PreTT is developing pretargeted radioligand therapies for cancer treatment. As a clinical-stage biotech, revenue will likely come from licensing deals, milestone payments, and eventual pharmaceutical partnerships. The company is pre-revenue and focused on R&D advancement.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

PreTT develops a proprietary pretargeted radioligand therapy (RLT) platform that separates non-radioactive monoclonal antibody accumulation and excretion from the actual administration of radioactivity, enabling precise targeting of cancer cells while minimizing radiotoxicity to healthy tissue. Its lead program, PRE-BREACH, extends this platform to glioblastoma by combining a blood-brain barrier-crossing shuttle antibody with pretargeted precision and alpha radiation delivery. The company is pre-revenue, operating at the preclinical stage with future commercialization planned through pharmaceutical licensing and partnerships.

Product overview

PreTT is a biotech company developing a unified pretargeted radioligand therapy (RLT) platform for cancer treatment. The platform consists of two integrated components: the core pretargeting technology that addresses the radiotoxicity challenges of traditional monoclonal antibody therapies by separating antibody accumulation from radiation delivery, and the PRE-BREACH project applying this technology to glioblastoma treatment using alpha radiation. The company operates at the preclinical development stage.

Differentiator

Problem solved

Functional benefit

Products and services

• Pretargeted Radioligand Therapy (RLT) Platform
• PRE-BREACH (uPAR Pretargeted Alpha Radioligand Therapy for Glioblastoma)

Quantifiable outcome

• Targeted delivery of alpha radiation with high precision to cancer cells while sparing surrounding healthy brain tissue
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Six partnerships are on record, tiered core and supporting.

• University of Copenhagen - Cluster for Molecular Imaging, Department of Biomedical SciencescoreStrategic or Co-development Partner · 30 April 2026Consortium partner contributing expertise in advanced molecular imaging and radioligand therapy for the PRE-BREACH project focused on pretargeted alpha radioligand therapy for glioblastoma.
• University of Copenhagen - Department of Drug Design and PharmacologycoreStrategic or Co-development Partner · 30 April 2026Consortium partner contributing radiochemistry expertise for the PRE-BREACH project developing innovative radiotherapy for glioblastoma.
• Rigshospitalet, Finsen LaboratorycoreStrategic or Co-development Partner · 30 April 2026Consortium partner specializing in antibody development for the PRE-BREACH project, contributing to the development of the shuttle mechanism antibody that crosses the blood-brain barrier.
• Curasight A/ScoreStrategic or Co-development Partner · 30 April 2026Consortium partner responsible for clinical and regulatory strategy within the PRE-BREACH project focused on pretargeted alpha radioligand therapy for glioblastoma.
• PanTarg ApScoreStrategic or Co-development Partner · 30 April 2026Consortium partner contributing expertise in target biology and antibody-based therapeutics for the PRE-BREACH project.
• BioInnovation Institute (BII)supportingOthersPreTT is based at the BioInnovation Institute (BII) in Copenhagen, which provides infrastructure and support for biotech startups. BII is a commercial foundation that supports life science start-ups.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Molecular Partners: Swiss clinical-stage biotech developing DARPin-based pretargeted radionuclide therapy (e.g., MP0712 radioligand program). Closely comparable to PreTT because both apply a pretargeting approach to overcome the slow tumor accumulation of larger targeting vectors in RLT.
• Aktis Oncology: US clinical-stage radiopharmaceutical company developing targeted alpha and beta radioconjugates for solid tumors. Comparable to PreTT in stage and modality (targeted RLTs with novel vector chemistries), and a likely M&A target in the same competitive set.
• Nordic Nanovector: Norway-based clinical-stage radiopharmaceutical company developing targeted radionuclide therapies for hematologic cancers. Relevant as a same-stage Nordic radiopharma peer and a useful negative reference point on clinical execution risk.
• Curasight: Copenhagen-based clinical-stage radiopharmaceutical company developing uPAR-targeted imaging and therapy. Already a consortium partner of PreTT in PRE-BREACH and the most directly comparable Danish/Scandinavian peer, sharing both uPAR targeting and Copenhagen ecosystem.

Broad incumbents

• Fusion Pharmaceuticals: Canadian targeted alpha therapy company (acquired by AstraZeneca in 2024) developing actinium-225-based RLTs. Comparable as a benchmark for valuation and partnership terms in the targeted alpha RLT space that PreTT is also pursuing.
• Point Biopharma: Radiopharmaceutical company developing next-generation radioligand therapies (acquired by Eli Lilly in 2024). Comparable as a strategic acquirer/partner archetype for PreTT and as a benchmark for pipeline scope in radioligands.
• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company with a portfolio of imaging and therapeutic RLTs (e.g., Illuccix). Comparable as a commercial benchmark for the addressable RLT market PreTT is positioning to enter with its next-generation pretargeting approach.
• Lantheus Holdings: US radiopharmaceutical-focused company with diagnostic and therapeutic RLT franchises (e.g., PNT2002). Comparable as an established radiopharma incumbent whose commercial performance anchors therapeutic RLT valuation benchmarks.
• Novartis (Radioligand Therapy): Pharma major with the leading approved radioligand therapies (Lutathera, Pluvicto). Comparable as the dominant incumbent in RLT whose pipeline direction sets the bar for PreTT's pretargeting platform and as the most likely large-pharma partner/acquirer.

Emerging players

• Nanobiotix: France-based clinical-stage nanomedicine company with a lead program in glioblastoma (NBTXR3, radioenhancer). Comparable as a similarly staged European oncology platform with a glioblastoma focus, though mechanistically distinct from pretargeted RLT.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pre-tt

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prett